<DOC>
	<DOCNO>NCT00287963</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , topotecan vinorelbine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose topotecan give together vinorelbine treat patient recurrent lung cancer .</brief_summary>
	<brief_title>Topotecan Vinorelbine Treating Patients With Recurrent Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose topotecan combine vinorelbine ditartrate patient recurrent lung cancer . Secondary - Assess response stable disease rate time disease progression among treated patient . OUTLINE : This dose-escalation study topotecan . Patents receive vinorelbine ditartrate IV 8-10 minute topotecan IV 30 minute day 1 8 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede ≥ 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm lung cancer All histologic type eligible Recurrent progressive disease ≥ 1 prior chemotherapy regimen without radiotherapy PATIENT CHARACTERISTICS : ECOG performance status ( PS ) ≤ 2 Karnofsky PS ≥ 60 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Total bilirubin ≤ 1.5 mg/dL Creatinine ≤ 1.5 mg/dL Not pregnant nursing Fertile patient must use effective contraception No active invasive malignancy No uncontrolled illness include , limited : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia No psychiatric illness/social situation would limit compliance study requirement No history allergic reaction attribute compound similar chemical biologic composition topotecan vinorelbine ditartrate PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 2 week since prior radiotherapy No prior therapy topotecan vinorelbine ditartrate No chemotherapy within past 4 week ( 6 week nitrosoureas mitomycin C ) Recovered agent administer &gt; 4 week earlier No concurrent investigational agent No concurrent palliative radiotherapy No concurrent anticancer therapy agents No concurrent hormones chemotherapy except follow : Steroids adrenal failure Hormones nondiseaserelated condition ( e.g. , insulin diabetes ) Intermittent dexamethasone antiemetic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>combine type small cell lung cancer</keyword>
	<keyword>intermediate type small cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>lymphocyte-like type small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>